Introduction and Objective: HDM1002 is an oral small molecule GLP-1RA under development for the treatment of T2DM and obesity. This study evaluated the efficacy and safety of HDM1002 in Chinese adult with T2DM inadequately controlled on diet and exercise(D&E) or metformin(Met).Methods: In this randomized, double-blind phase 2 study, patients were randomized in a 1:1:1:1:1 ratio […]
Read MoreMonth: June 2026
1205-OR: Tissue-Specific Mitochondrial Adaptations Parallel Metabolic Improvements after Bariatric Surgery
Introduction and Objective: Humans with obesity-related insulin resistance (IR) and metabolic dysfunction-associated steatotic liver disease (MASLD) show different mitochondrial alterations. While oxidative phosphorylation (OXPHOS) can be increased in liver, it may be decreased in visceral (VAT), but neither in subcutaneous adipose tissue (SAT) nor skeletal muscle (SM). However, it remains unclear how weight loss affects […]
Read More1202-OR: Aptamer-Driven Immunomodulation of Human Islets: Combating IBMIR for Clinical Translation
Introduction and Objective: Instant blood-mediated inflammatory reaction (IBMIR) causes rapid loss of up to 50% of transplanted islet mass, primarily through inflammatory and coagulation pathways. Blocking these mediators is critical for improving graft survival. We hypothesized that aptamers targeting interleukin 1 beta (IL-1β), tumor necrosis factor-alpha (TNFα), and factor VIIa (FVIIa) could attenuate IBMIR and […]
Read More1183-OR: Low-Carbohydrate Diets, Nutritional Adequacy, Glycaemia, and Perinatal Outcomes in Women with Gestational Diabetes. A Secondary Analysis of the DiGest Trial
Introduction and Objective: The optimal dietary carbohydrate intake for pregnant women is disputed internationally. Some authorities recommend consuming >175g/d of carbohydrate aiming to support safe placental function; others use carbohydrate restriction to ≤120g/d to reduce hyperglycemia in gestational diabetes. We assessed if consumption of a low (<175g/d) or very low (<120g/d) habitual carbohydrate intake was […]
Read More1189-OR: Axon Guidance Signaling in Adipose Tissue Development and Function
Introduction and Objective: Activating and expanding brown adipose tissue (BAT) offer promising strategies to counteract obesity and cardiometabolic diseases. Due to their high metabolic activity, brown adipocytes act as a metabolic sink and improves glucose and lipid metabolism. Adipose depots are highly vascularized and innervated, containing an extensive network of capillaries and sympathetic nerves that […]
Read More1182-OR: Dietary Quality Factors Associated with CGM-Derived Gestational Glycemia
Introduction and Objective: Little is known about how diet quality is related to gestational glycemia and neonatal birthweight.Methods: From 2/2023 to 2/2024, singleton gravidas without preexisting diabetes and enrolled in GO MOMs, a multicenter study of glycemia across pregnancy, completed Automated Self-Administered 24-Hour Dietary Assessment recalls: up to 3 at 10-20 wks’ gestation, and up […]
Read More1161-OR: Lifestyle Changes (LC) among Participants in Trials of Disease Modifying Therapies (DMT) in Type 1 Diabetes (T1D)
Introduction and Objective: Individuals with early stage T1D may engage in LC (e.g., carbohydrate restriction, vitamin use) to delay progression. Little is known about use of LC in individuals in DMT trials. We characterized LC reported in DMT trials conducted by TrialNet.Methods: We analyzed pooled participant questionnaires from 6 DMT trials for prevention (n=4) or […]
Read More1178-OR: Population Impact of State-Level Insulin Out-of-Pocket Caps
Introduction and Objective: The high cost of insulin hinders access and utilization of insulin, a life-sustaining medication, for U.S. adults with diabetes. By 2025, 27 states and DC have passed and implemented insulin out-of-pocket (OOP) caps, but the reach of these caps is uncertain. In this study, we estimate the population being protected by state […]
Read More1159-OR: Understanding CGM Breaks in Emerging Adults with Type 1 Diabetes: Prevalence, Drivers, and Impacts
Introduction and Objective: Emerging adults (EAs) with type 1 diabetes (T1D) face elevated A1c levels and diabetes distress. Continuous glucose monitors (CGM) improve outcomes, but little is known about CGM breaks – particularly during this developmental period. Using mixed methods, we investigated the prevalence, drivers, behaviors during, and impacts of CGM breaks through surveys and […]
Read More1169-OR: Technology, Pharmacology, or Both? Real-World Effectiveness of CGM and GLP-1 Therapy in Primary Care
Introduction and Objective: CGM and GLP-1 receptor agonists (RA) are two distinct and increasingly used treatment strategies in T2D, each associated with meaningful improvements in clinical outcomes. However, there is little real-world evidence comparing their effectiveness in primary care or evaluating whether combined use offers added benefit in HbA1c and body weight (BW).Methods: We conducted […]
Read More